Altered responsiveness of regional brain dopamine and DOPAC levels to systemic administration of quinpirole, a dopamine D2 agonist, in DOCA/NaCl-hypertensive rats

Our previous studies have demonstrated that administration of quinpirole (LY171555), a potent and highly selective dopamine (DA) D2 receptor agonist, to conscious Sprague-Dawley rats produces increases in arterial pressure through the activation of sympathetic outflow and vasopressinergic activity. To test the hypotheses that quinpirole inhibits in vivo release of DA from central dopaminergic neurons by activation of DA receptors in the central nervous system (CNS) and that this mechanism may be altered in the desoxycorticosterone acetate (DOCA)/NaCl model of hypertension, we examined the effects of quinpirole on stores of DA and its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in brain regions of 4-week DOCA/NaCl-hypertensive rats and their normotensive controls. Levels of DA and DOPAC were measured in brain regions by HPLC 15 min after the i.v. administration of quinpirole (1 mg/kg). Quinpirole resulted in a significant increase in DA stores and decrease in DOPAC stores in most brain regions examined in both DOCA/NaCl-hypertensive rats and normotensive controls, presumably by inhibiting DA release through a presynaptic mechanism. In the vehicle-treated groups, DA stores in the anterior hypothalamus and DOPAC stores in the nucleus accumbens were lower in DOCA/NaCl-hypertensive rats than in H2O controls. Following quinpirole administration, DA stores in the anterior hypothalamus increased significantly in DOCA/NaCl-treated rats but not in H2O controls and DOPAC stores in the nucleus accumbens decreased significantly in H2O control rats but not in DOCA/NaCl-treated rats. These observations provide further evidence for the presence of inhibitory DA D2 receptors which modulate the activity of dopaminergic neurons in the CNS.(ABSTRACT TRUNCATED AT 250 WORDS)     

The neuroleptic-like peptide desenkephalin-γ-endorphin does not antagonize the dopamine receptor agonist-induced inhibition of the release of [H]dopamine from rat nucleus accumbens slices in vitro

In rats, the non-opioid β-endorphin (βE) fragment desenkephalin-γ-endorphin (DEγE, βE_6–17) antagonizes the hypomotility induced by a small dose of dopamine (DA) receptor agonists. It has been suggested that DEγE might act in this respect by a direct or indirect blockade of presynaptically located DA receptors in the nucleus accumbens, thereby causing an increase of DA release. Therefore in the present study the effect of DEγE was examined on DA receptor agonist-induced inhibition of the electrically evoked release of previously accumulated [³H]DA from rat nucleus accumbens slices in vitro. The DA receptor agonists apomorphine, LY 171555 andn,n-di-n-propyl-7-hydroxy-2-aminotetralin (DP-7-AT) inhibited in a concentration-dependent manner the electrically evoked release of [³H]DA. The selective D₂ receptor antagonist (−)-sulpiride blocked the effects of apomorphine, corroborating that the DA receptor involved is of a D₂ type. DEγE was tested at several concentrations (10⁻⁹–10⁻⁶) and under various experimental conditions. DEγE, by itself, did not affect either the electrically stimulated or the basal release of [³H]DA. The inhibiting effect of DA receptor agonists was slightly reduced by DEγE, but this effect was present in some experiments only. It is concluded that DEγE does not function as an antagonist for the DA receptor mediating DA release and that the interaction observed in behavioural experiments between DA agonists and DEγE does not occur at the level of this receptor.     

Blunted responsiveness of posterior hypothalamic norepinephrine to quinpirole in DOCA/NaCl hypertensive rats

Our previous studies have demonstrated that the specific dopamine D2 receptor agonist, quinpirole (LY171555), has a pressor effect in conscious normotensive rats and that this is accompanied by a centrally mediated increase in sympathetic activity and arginine vasopressin release. This pressor response to quinpirole is blunted in the DOCA/NaCl hypertensive rat. To examine the hypothesis that the responsiveness of the central noradrenergic and serotonergic systems to quinpirole treatment is altered in DOCA/NaCl rats, the norepinephrine (NE), serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) contents of hypothalamic and brainstem areas were measured in 4-week DOCA/NaCl hypertensive and H2O control rats 15 minutes after the intravenous administration of quinpirole (1 mg/kg). The results demonstrate that quinpirole selectively reduced (26%) posterior hypothalamic NE content in control rats, but not in DOCA/NaCl hypertensive rats. The NE content in the spinal cord and 5-HIAA content in the pons were greater in DOCA/NaCl rats than in normotensive controls in both saline and quinpirole treated groups. Our data suggest that the specific D2 agonist may effect its central pressor response by stimulating NE release from posterior hypothalamic area, a "pressor" region of hypothalamus, and that this D2 agonist induced pressor mechanism may be blunted in DOCA/NaCl hypertension.     

Evidence for dopamine as a transmitter in dorsal hippocampus

Intrahippocampal distribution of dopamine (DA) and its metabolites, homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), was studied along with those of noradrenaline (NA) and 5-hydroxytryptamine in rats. DA concentration in the dorsal part of the hippocampus was found to be 4–10 times higher than in other parts. A study of metabolite distributions produced similar results, showing a higher concentration in the dorsal part of the hippocampus. A ratio of NA/DA had a value similar to that of the hypothalamus in which apparent dopaminergic innervation has been reported. Haloperidol decreased the DA level, whereas it increased the concentration of metabolites, in whole and dorsal hippocampus. The ratio HVA/DOPAC increased after haloperidol treatment. These findings strongly suggest the presence of dopaminergic innervation in at least the dorsal part of the hippocampus.     

Effects of two diketopiperazines, cyclo (His-Pro) and Cyclo (Asp-Phe), on striatal dopamine: A microdialysis study

The effects of two diketopiperazines, Cyclo (His-Pro) (CHP) and Cyclo (Asp-Phe) (CAP), on striatal extracellular levels of dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA) were examined using in vivo microdialysis in anaesthetized rats. Treatment with neither CHP (0.1–10 mg/kg IP and 0.3 mg/kg IV) nor CAP (0.1–10 mg/kg IP and 10 mg/kg PO) significantly changed the efflux of DA, DOPAC, HVA, or 5-HIAA when compared to the effects of treatment with saline. Our results suggest that systemic administration of CHP or CAP alone does not modify striatal dopaminergic neurotransmission. The previous findings of enhanced DA release by systemic administration of thyrotropin releasing hormone (TRH) are probably not explained by formation of CHP from TRH.     

Regulation of dopamine release and metabolism in rat striatum in vivo: Effects of dopamine receptor antagonists

1. 1. The acute effects of some of typical and atypical antipsychotic drugs on the dopamine release and metabolism in the dorsal striatum of freely moving rats were studied using transcerebral microdialysis technique.

2. 2. Classical neuroleptic drugs haloperidol (0.05, 0.1 and 0.2 mg/kg), thioproperazine (0.1, 0.2 and 0.4 mg/kg) and spiperone (0.02, 0.04 and 0.07 mg/kg) administered i.p. induced pronounced elevation of extracellular level of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) up to 250–300 % to basal level while producing less increase in that of dopamine (DA) (up to 150–170 %).

3. 3. Atypical neuroleptics clozapine and thioridazine (both 2, 5 and 20 mg/kg) increased striatal DA release and DOPAC level approximately at the same degree (maximally up to 200% and 160%, respectively).

4. 4. Dopamine D3 receptor and autoreceptor preferring antagonists (+)-UH232 and (+)-AJ76 (both 4, 7 and 14 mg/kg) more potently increased DA release in comparison with DOPAC dialysate level ( (+)-AJ76 elevated DA level maximally up to 330 %, DOPAC - up to 250 %).

5. 5. The features of typical and atypical neuroleptics in preferential action on DA release or DOPAC output were observed in all doses of the drugs studied .

6. 6. The ability of the drugs to affect preferentially DA release or DOPAC extracellular level in rat striatum correlates to their relative affinities at D3 and D2 DA receptors.

7. 7. It is concluded that typical and atypical antipsychotic drugs might be clearly distinguished on the basis of their ability to affect preferentially DA synthesis/metabolism or release in rat dorsal striatum in vivo.

     

止颤汤干预神经干细胞移植帕金森病大鼠脑内多巴胺及其代谢产物的变化*

背景：如何促进脑内多巴胺含量的增加以及减少多巴胺的代谢,是治疗帕金森病的热点所在。 目的：从多巴胺代谢途径角度观察止颤汤对神经干细胞移植帕金森病大鼠的脑黑质中多巴胺及其代谢产物含量的变化。 方法：以大鼠脑立体定位和1-甲基-4-苯基-1,2,3,6-四氢吡啶建立帕金森病大鼠模型。应用高效液相色谱法测定帕金森病大鼠中脑多巴胺及其代谢产物的含量。 结果与结论：止颤汤可以提高神经干细胞移植后帕金森病大鼠中脑多巴胺及其代谢产物双羟苯乙酸的含量,但对代谢产物高香草酸无明显影响。通过促进帕金森病大鼠干细胞移植后神经干细胞的存活,使之定向分化为多巴胺能神经元并分泌多巴胺,同时抑制多巴胺分解达到治疗作用。     

Diurnal changes of tyrosine, dopamine, and dopamine metabolites content in the retina of rats maintained at different lighting conditions

The aim of the study was to investigate the daily rhythms of tyrosine (Tyr), dopamine (DA), 3,4-dioxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) content in the retina of rats maintained under different lighting conditions. Studied substances were measured by highly sensitive high-performance liquid chromatography (HPLC) with an electrochemical detection method. It was found that the levels of Tyr, DA, DOPAC, and HVA change diurnally in the retina of adult Wistar rats maintained under standard cyclic lighting (12-h light/12-h dark). The maximum was found during the light phase of 12:12 light:dark photoperiod. Diurnal changes of DA, DOPAC, and HVA persisted in constant darkness. When the rats were maintained in constant lighting conditions for 2 d (light intensity, 200 1x), the rhythms of tyrosine, DA, and DOPAC completely disappeared. However the level of HVA was higher during the subjective day. The presence of diurnal rhythm of melatonin content in the retina of rats was confirmed by HPLC with an amperometric detection method. Since the presence of time cues is not necessary for manifestation of diurnal changes of DA and its metabolite content, it was concluded that the circadian oscillator drives these rhythms. Probably DA can serve as a zeitgeber for retinal circadian rhythms.     

Presynaptic D2 dopaminergic receptors mediate inhibition of excitatory synaptic transmission in rat neostriatum

The effect of dopamine (DA) on excitatory synaptic transmission was studied in rat neostriatal neurons using intracellular- and whole-cell voltage clamp-recording methods. Depolarizing excitatory postsynaptic potentials (EPSPs) were evoked by cortical stimulation. Superfusion of DA (0.01–10 μM) reversibly decreases EPSP in a concentration-dependent manner and with a estimated IC₅ of 0.3 μM. In addition, the inhibitory effect induced by DA at a low concentratiion (0.1 μM) was antagonized by sulpiride (1–10 nM), a selective D₂ dopaminergic receptor antagonist. However, D₁ dopaminergic receptor antagonist SKF-83566 (1–5 μM) did not affect the blocking effect by DA 0.1 μM. Based on these findings, we conclude that DA at a low concentration ( 0.1 μM) reduced the excitatory response of neostriatal neurons following cortical stimulation via the activation of D₂, but not D₁ dopaminergic receptors, located on the terminals of corticostriatal neurons.     

Attenuated extracellular dopamine levels after stress and amphetamine in the nucleus accumbens of rats with neonatal ventral hippocampal damage

Summary. In vivo microdialysis was used to study the effects of restraint stress (30 min) and amphetamine (AMPH) (5 mg/kg, i.p.) in awake adult male rats with neonatal ventral hippocampal (VH) damage. Extracellular levels of dopamine (DA), dihydrophenylacetate (DOPAC), homovanillate (HVA) and 5-hydroxyindolacetate (5-HIAA) were measured in the nucleus accumbens (NA). There were no differences in the baseline levels of DA, DOPAC, HVA or 5-HIAA in the lesioned as compared to the sham rats. Release from restraint resulted in increased extracellular levels of DA in the sham but not in the lesioned animals. AMPH increased DA release in both sham operated and lesioned animals, but this increase was significantly attenuated in the lesioned rats. Our data suggest that this developmental lesion alters function of the dopaminergic system in response to environmental and pharmacological challenge. Received June 3, 1997; accepted August 10, 1998     

The in vivo microdialysis recovery of dopamine is altered independently of basal level by 6-hydroxydopamine lesions to the nucleus accumbens

The present study was designed to test the hypothesis that the active neurotransmitter processes of release and uptake affect the in vivo microdialysis recovery of dopamine (DA) in the nucleus accumbens (N ACC) of the rat. The in vivo recovery for DA was established for rats which had received either unilateral infusions of the neurotoxin 6-hydroxydopamine (6-OHDA, 8 μg) or vehicle (0.2 μg ascorbate). In the quantitative dialysis method used (point of no net flux method), DA is added to the perfusate at concentrations above and below the expected extracellular concentration (0, 5, 10 and 20 nM) and DA is measured in the dialysate from the brain to generate a series of points. A linear fit is performed, the slope of which is the in vivo recovery of the dialysis probe. The in vivo recovery of the 6-OHDA group was 30 ± 3% which was significantly lower (P < 0.002) than the in vivo recovery of the control group which was 60 ± 3% (mean ± SEM; n = 6/group). The zero intercept of this regression is the point of no net flux, which is the extracellular concentration of DA independent of the probe sampling characteristics. The extracellular DA concentration for the 6-OHDA group was 7.8 ± 1.1nM, which was not significantly different than the control group which was 6.9 ± 0.7nM. The tissue DOPAC/DA ratios of the 6-OHDA lesioned hemispheres were significantly higher than the contralateral hemispheres of the same animals (0.62 ± 0.1vs.0.27 ± 0.1; P < 0.02) while the DOPAC/DA ratios in the control group were not significantly different (0.24 ± 0.1vs.0.27 ± 0.1). The fractional DA efflux from the terminals in the 6-OHDA group was significantly higher than the fractional DA efflux of the control group (0.52 ± 0.08vs.0.03 ± 0.003; P < 0.0001), indicating that the remaining terminals have increased turnover of DA. Despite the increased turnover, however, the number of remaining release and uptake sites are not sufficient to maintain the high in vivo recovery observed in the control group.     

Dynamic regulation of striatal dopaminergic grafts during locomotor activity

The present experiment was designed to estimate the neurochemical activity of dopaminergic grafts in hemiparkinsonian model rats during locomotion and to examine the functional importance of dynamic regulation of the grafted neurons in the host brain. Rats were trained to run on a straight treadmill at various speeds (300, 660, 1200, 1800 cm/min), and extracellular dopamine (DA) and its metabolites, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), were measured by in vivo microdialysis during and after running. Grafted rats were divided into two groups depending on their running ability and data were compared with those of normal and lesioned controls. Although the tonic level of extracellular DA in grafted rats recovered to 70% of control, levels of DOPAC and HVA remained 15–20% of controls. A small number of grafted rats showed full recovery in treadmill running tasks. In these animals, the percentage increase in DOPAC and HVA showed similar time courses and magnitudes as those in normal rats. Most grafted rats showed partial recovery in locomotor ability. The percentage increase in DOPAC and HVA in these animals remained at a lower level than that in normal rats, though the tonic levels of DA, DOPAC and HVA were not lower than those of fully recovered rats. Data suggest that grafted DAergic cells in functionally well recovered rats were dynamically regulated in the host brain in an actual behavior and that well-controlled release of DA might be involved in the recovery of complex motor behavior, such as high speed locomotion.     

Evidence for the existence of prejunctional receptor sites for dopamine in the mouse vas deferens

The present work is focused on the effects of newly developed dopaminergic agonists and antagonists on the field-stimulated vas deferens. Both LY 171555 and SK&F 38393, relatively selective DA2 and DA1 receptor agonists, respectively, produced concentration-dependent inhibition of the field stimulation-evoked contractions in the mouse vas deferens; both compounds did not modify the baseline tone nor the contractile responses to exogenous noradrenaline. Control LY 171555 and SK&F 38393 concentration-response curves, were shifted rightward in a parallel manner in the presence of sulpiride (relatively specific DA2 antagonist) and SCH 23390 (relatively specific DA1 antagonist), respectively. Control concentration-response curves for dopaminergic agonists were not modified in the presence of specific blockers for H1 and H2 histamine receptors, serotonin receptors and alpha 2-adrenoceptors. These preliminary findings are suggestive of the existence of two dopaminergic receptor types both presumably located prejunctionally.     

Dopamine synthesis in inbred mouse strains which differ in numbers of dopamine neurons

BALB/cJ and CBA/J mice have been shown to have different numbers of dopamine (DA) neurons in the central nervous system, with BALB/cJ mice having 20–50% more DA neurons in each dopaminergic cell group which is reflected in a difference in tyrosine hydroxylase activity in these cell groups. The present study compared the levels of DA and the rate of DA synthesis between these two inbred mouse strains. Three measures were used to reflect the rate of DA synthesis: the levels of DA metabolites (DOPAC and HVA) in the striatum, the rate of disappearance of DA following inhibition of tyrosine hydroxylase withα-methyl-P-tyrosine, and the rate of accumulation of DOPA following inhibition of aromatic amino acid decar☐ylase with NSD-1015. Striatal DA levels were slightly higher in CBA/J mice than BALB/cJ mice. The rate of DA synthesis in the striatum, as estimated from the accumulation of DOPA following NSD-1015 injection or from the decline of DA levels followingα-methyl-p-tyrosineinjection, was from 30–50% greater in the BALB/cJ mice compared to the CBA/J mice. In striatum, DOPAC levels were higher, HVA levels lower, and DOPAC plus HVA levels equal in CBA/J mice compared to BALB/cJ mice. The results show that BALB/cJ mice, with more DA neurons than CBA mice, also synthesize more DA. In addition, the data suggest that DA levels do not necessarily reflect numbers of DA neurons, and that catecholamine metabolite levels are not a good measure for comparing catecholamine synthesis between inbred animal strains.     

In vivo microdialysis studies of age-related alterations in potassium-evoked overflow of dopamine in the dorsal striatum of Fischer 344 rats

Intracerebral microdialysis was used to measure basal levels and potassium (K(+))-stimulated overflow of dopamine (DA), homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC), in the dorsal striatum of young (6 months) and aged (24 months) Fischer 344 (F344) rats. Basal levels of HVA were lower in aged rats whereas basal DA and DOPAC did not differ significantly between the two groups. The administration of three low to moderate doses of K(+) (10, 25, and 50 mM) through the microdialysis probe for one collection period revealed differences between the two age groups of F344 rats. DA overflow increased in a dose-dependent manner in the young but not aged rats. Extracellular levels of DOPAC and HVA decreased during the K(+) stimulation and there was a significant difference in the changes in HVA produced by K(+) stimulation in the young vs aged animals. These data support the hypothesis that low to moderate doses of K(+) may be necessary to demonstrate age-related differences in K(+)-evoked DA overflow, since previous microdialysis studies using higher doses have not reported age-related differences in DA overflow.     

Cyclo (His-Pro), d-amphetamine and striatal dopamine: a microdialysis study

Extracellular levels of dopamine (DA) and its metabolites (DOPAC and HVA) were monitored in the striatum of rats using in vivo microdialysis, in an attempt to elucidate the mechanism of cyclo (His-Pro) (histidyl-proline-diketopiperazine, CHP) on dopaminergic activity. Pretreatment with CHP (0.5 mg/kg SC) (n = 5) or the equivalent volume of saline (n = 5) was followed 30 min later by 5 mg/kg IP of d-amphetamine. Dialysate samples were collected and analyzed by high performance liquid chromatography with electrochemical detection (HPLC-EC). Following the initial increase in DA caused by d-amphetamine, DA levels of CHP-treated rats were significantly lower than saline-treated rats across time (p less than 0.05). No difference was observed for DOPAC or HVA. It is therefore unlikely that CHP interferes with the d-amphetamine-induced inhibition of DA reuptake. Other neurotransmitter systems may be involved in the CHP-induced augmentation of amphetamine's behavioral effects. Our data, as well as previous findings, suggest that attenuation of the dopaminergic response to d-amphetamine might be best explained on the basis of striatal DA depletion, possibly via tyrosine hydroxylase (TH) inhibition. This study also indicates that a dissociation may exist between the behavioral and the striatal DA response to acute amphetamine. The data support the hypothesis that amphetamine releases DA from a newly synthesized, extravesicular cytoplasmic pool, and that intracellular striatal DA is present in considerable excess relative to the extracellular DA.     

Increased striatal dopamine turnover following acute administration of rotenone to mice

Because of the potential role of mitochondrial dysfunction in nigrostriatal degeneration in Parkinson's disease, the effects of rotenone (an inhibitor of mitochondrial NADH dehydrogenase and a naturally occurring toxicant) on the levels of striatal dopamine (DA) and DA metabolites were evaluated after acute and subchronic administration to mice. Systemic acute treatment with relatively high doses of rotenone did not affect DA concentration, but caused a significant increase in both DA metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). DOPAC and HVA changes were measured at 1 day and were reversed within 1 week, paralleling the time course of rotenone-induced increase in striatal lactate levels. Subchronic administration with a relatively mild dose of rotenone did not significantly alter the striatal levels of DA and DOPAC, while it slightly reduced HVA concentration. No neurochemical signs of dopaminergic damage were seen when mice were co-exposed to rotenone and diethyldithiocarbamate, a compound known to enhance nigrostriatal injury caused by the neurotoxicant 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP). Also, rotenone did not cause additional injury to animals previously lesioned by MPTP. Taken together, data indicate that rotenone is not capable of causing overt dopaminergic toxicity under the testing paradigms used in this study. Rather, an increase in DA turnover, as indicated by a higher (DOPAC+HVA)/DA ratio, seems to be associated to rotenone-induced striatal energy impairment.     

Differential effect of self-stimulation on dopamine release and metabolism in the rat medial frontal cortex, nucleus accumbens and striatum studied by in vivo microdialysis.

Changes in the extracellular levels of dopamine (DA) and its metabolites in the dopaminergic terminal regions, the medial frontal cortex (MFC), nucleus accumbens (NAC), and striatum (STR), were measured by microdialysis during self-stimulation of the medial forebrain bundle (MFB) in rats pretreated with the DA uptake inhibitor, nomifensine (1 mg/kg, i.p.). Self-stimulation of the MFB in nomifensine-pretreated rats caused an increase in the extracellular DA level in the MFC and NAC but not in the STR. Self-stimulation also increased the extracellular concentrations of the main DA metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) to a similar extent in the MFC and NAC and to a lesser extent in the STR. Thus, there was a regional difference in the neurochemical changes following self-stimulation with either the MFC or the NAC showing larger extracellular levels of DA, DOPAC, and HVA than the STR. Furthermore, these changes were observed on both hemispheres ipsilateral and contralateral to the stimulation. The results indicate that self-stimulation of the MFB preferentially activates the mesocorticolimbic DA systems, thereby bilateral increases in the release of DA and its metabolism being produced in their terminal regions, the MFC and NAC.     

Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: Time course and time-dependent interactions with amfonelic acid

The administration of a single dose of (+)-amphetamine sulfate (9.2 mg/kg) to rats treated with iprindole hydrochloride (10 mg/kg) produced marked decreases in the striatal concentrations of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) one week after drug administration. Significant changes were not observed in striatal 5-hydroxyindoleacetic acid (5-HIAA) nor in norepinephrine, DA, DOPAC, HVA, and 5-HIAA concentrations in frontal cortex and a limbic forebrain sample containing primarily nucleus accumbens and olfactory tubercles. In time-course experiments, decreases in striatal DA were apparent by 12 h after amphetamine plus iprindole administration and persisted for at least 4 weeks. Decreases in striatal DOPAC and HVA followed a similar time course, except decreases in these parameters were observed at 6 h as well. The administration of amfonelic acid, a potent DA uptake inhibitor, up to 8 h but not at 12 h after amphetamine administration prevented the decreases in striatal DA, DOPAC and HVA at one week after the administration of the drug to iprindole-treated rats. These data indicate that the actions of amphetamine which are necessary and sufficient for the production of long-term decreases in striatal DA, DOPAC and HVA are dependent upon the integrity of the neuronal uptake mechanism for DA and occur within 12 h after the administration of amphetamine to iprindole-treated rats. Although amfonelic acid prevented the long-term effects of amphetamine on striatal DA neurons, it did not alter the decrease in DOPAC produced by amphetamine at 6 h after the administration of amphetamine plus iprindole. This finding suggests that the ability of amfonelic acid to prevent the long-term effects of amphetamine on striatal DA neurons in iprindole-treated rats is not due to a blockade of the entry of amphetamine into the neuron and, thus, suggests that the access of amphetamine to the inside of the neuron is not sufficient for the production of its long-term, possibly neurotoxic, effects on striatal DA neurons.     

Development of dopamine receptors in the forebrain of the domestic chick in relation to auditory imprinting. An autoradiographic study

The rostro-medial neostriatum/hyperstriatum ventrale (MNH) and the neostriatum dorsocaudale (Ndc) are forebrain regions which play a role in auditory filial imprinting. Both regions receive a distinct dopaminergic input from the mesencephalon and we were interested to investigate if the dopaminergic system, which is known to play a role in associative learning processes and neuronal plasticity is involved in auditory imprinting. Using ligand autoradiography we studied the distribution and density of dopamine receptors (D₁ and D₂ type) in the forebrain of socially isolated chicks during the first postnatal week and compared these data with the values of age-matched imprinted chicks. D₁- and D₂-receptors were present in the chick forebrain on the day of hatching and they showed in general, the same distribution until postnatal day 7. Between days 0 and 2 the D₂-receptor density increased significantly in the lobus parolfactorius and paleostriatum augmentatum while for D₁-receptor density no significant changes were detectable. The receptor densities in the investigated forebrain regions did not differ significantly between imprinted and control chicks. These results suggest that auditory imprinting does not induce alterations of dopamine receptor density, however, more subtle changes can not be excluded. The presented detailed data about the developmental profile of dopamine receptors within distinct brain regions is a further step towards a more specific interpretation of behavioral effects of dopamine receptor agonists or antagonists at different postnatal ages.